All In Biotech

Drug Trial Radar · NCT02275117

A Multicenter Assessment of ALD403 in Chronic Migraine

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine

Last checked: Nov 20, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 665 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

665

Actual

Start

Oct 2014

Primary completion

Mar 2016

Study completion Nov 2016

Sponsor

Lead sponsor
Alder Biopharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

Conditions

  • Migraine Disorders

Interventions

  • ALD403Biological

  • PlaceboBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 75% Migraine Responder RateTime frame: 12 Weeks

Locations

92 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Encino, California

  • Reserach Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Oakland, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Monica, California

  • Research Site

    Stanford, California

  • Research Site

    Ventura, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Stamford, Connecticut

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Gainesville, Florida

  • Research Site

    Hallandale, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    North Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Evansville, Illinois

  • Research Site

    Normal, Illinois

  • Research Site

    Prairie Village, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Shreveport, Louisiana

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.